Conformis, Inc. (CFMS): Price and Financial Metrics
CFMS Stock Summary
- Conformis Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 94.06% of US listed stocks.
- CFMS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 80.55% of US stocks.
- Conformis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -16.06%, greater than the shareholder yield of only 14.56% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Conformis Inc, a group of peers worth examining would be NSPR, SHSP, ATRI, BRKS, and AUTO.
- CFMS's SEC filings can be seen here. And to visit Conformis Inc's official web site, go to www.conformis.com.
CFMS Stock Price Chart Interactive Chart >
CFMS Price/Volume Stats
|Current price||$0.86||52-week high||$1.49|
|Prev. close||$0.81||52-week low||$0.60|
|Day high||$0.89||Avg. volume||5,221,760|
|50-day MA||$1.01||Dividend yield||N/A|
|200-day MA||$0.84||Market Cap||156.89M|
Conformis, Inc. (CFMS) Company Bio
ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. The company was founded in 2004 and is based in Bedford, Massachusetts.
CFMS Latest News Stream
|Loading, please wait...|
CFMS Latest Social Stream
View Full CFMS Social Stream
Latest CFMS News From Around the Web
Below are the latest news stories about Conformis Inc that investors may wish to consider to help them evaluate CFMS as an investment opportunity.
Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to ExpandBILLERICA, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a license agreement with Paragon 28, Inc., granting Paragon 28 a non-exclusive license under a subset of Conformis’ U.S. patents for the use of patient-specific instruments with off-the-shelf implants in Paragon 28’s APEX 3D™ Total Ankle Replacement System. “We are pleased to reach this agreement with Paragon 28, enabling it to incorporate our patient-specific instrument technology in its anticipated total ankle replacement offering,” said Mark Augusti, President and Chief Executive Officer. “We believe that this latest license agreement further demonstrates the broad a...
Investors are optimistic about STERIS (STE) backed by elevated consumer demand and strong segmental growth in third-quarter fiscal 2021.
Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.
BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Wednesday, May 5, 2021, at 4:30 p.m. Eastern Time to discuss the financial results and to provide a business update. The webcast will be live at: https://edge.media-server.com/mmc/p/vnzdh2h9. To attend by telephone, please use the information below for dial-in access. When prompted on dial-in, please utilize conference ID: 8727027.Participant conference numbers (877) 809-6331 (U.S./Canada) and (615) 247-0224 (International).Please dial in at...
Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.
CFMS Price Returns
Continue Researching CFMSHere are a few links from around the web to help you further your research on Conformis Inc's stock as an investment opportunity:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!